Albireo Pharma, Inc. (ALBO) EPS Estimated At $3.75

May 16, 2018 - By Margaret Downey

Analysts expect Albireo Pharma, Inc. (NASDAQ:ALBO) to report $3.75 EPS on May, 17 before the open.They anticipate $4.81 EPS change or 453.77 % from last quarter’s $-1.06 EPS. ALBO’s profit would be $44.78 million giving it 2.09 P/E if the $3.75 EPS is correct. After having $-0.55 EPS previously, Albireo Pharma, Inc.’s analysts see -781.82 % EPS growth. The stock increased 1.72% or $0.53 during the last trading session, reaching $31.38. About 129,786 shares traded or 149.15% up from the average. Albireo Pharma, Inc. (NASDAQ:ALBO) has risen 43.49% since May 16, 2017 and is uptrending. It has outperformed by 31.94% the S&P500.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders in the United States. The company has market cap of $374.74 million. The Company’s lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. It currently has negative earnings. The company's clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption.

More important recent Albireo Pharma, Inc. (NASDAQ:ALBO) news were published by: Nasdaq.com which released: “Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting” on April 19, 2018, also Globenewswire.com published article titled: “Albireo to Present at Deutsche Bank 43rd Annual Health Care Conference”, Nasdaq.com published: “Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018” on May 09, 2018. More interesting news about Albireo Pharma, Inc. (NASDAQ:ALBO) was released by: Streetinsider.com and their article: “Jefferies Starts Albireo Pharma (ALBO) at Buy” with publication date: April 20, 2018.

Albireo Pharma, Inc. (NASDAQ:ALBO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: